[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601094":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":85,"collaborators":87,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":29,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":29,"studyType":104,"phases":105,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Kenai Therapeutics","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"First patient group","EXPERIMENTAL","Low dose",[13,14],"Biological: RNDP-001","Device: Syringe Front-Loading Device",{"label":16,"type":10,"description":17,"interventionNames":18},"Second patient group","High dose",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Third patient group","Best dose",[13,14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"BIOLOGICAL","RNDP-001","Stem cells",[9,16,20],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"DEVICE","Syringe Front-Loading Device","Delivers the stem cells",[9,16,20],[36],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"General Inquiries","CONTACT","\u003Cneed to obtain>","patients@kenaitx.com",[42,61,71],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Arizona","RECRUITING","Tucson","Arizona","85721","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-110.92648,32.22174,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":59,"phoneExt":29,"email":60},"Marisa Valletta","1 (520) 626-7322","COM-Neurosurgtrials@arizona.edu",{"facility":62,"status":44,"city":63,"state":64,"zip":65,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":29},"Keck Medical Center of University of Southern California","Los Angeles","California","90033",{"type":51,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},{"facility":72,"status":44,"city":73,"state":74,"zip":75,"country":48,"countryCode":49,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43210",{"type":51,"coordinates":77},[78,79],-82.99879,39.96118,{"lat":79,"lon":78},[82],{"name":29,"role":38,"phone":83,"phoneExt":29,"email":84},"1 (614) 366-1648","Caitlyn.Evanovich@osumc.edu",{"type":86,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[88],{"name":89,"class":90},"California Institute for Regenerative Medicine (CIRM)","OTHER","100601094","phase-1-a-study-to-assess-safety-and-efficacy-of-surgical-implant-of-rndp-001-in-patients-with-idiopathic-parkinsons-disease-100601094",false,"NCT07106021","A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease","A Phase 1b\u002F2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease consistent with the Movement Disorders Society Clinical Criteria\n* Age 45 to 75\n* Medically stable to undergo a surgical procedure\n\nExclusion Criteria:\n\n* Known Parkinson's disease gene mutation or variant\n* Previous infusion therapy or surgery for Parkinson's disease\n* History of allergic reaction or intolerance to an immunotherapeutic agent\n* Contraindication to MRI\n* Clinically significant medical conditions likely to interfere with the surgical procedure or study assessments","ALL","45 Years","75 Years",{"count":102,"type":103},12,"ESTIMATED","INTERVENTIONAL",[106,107],"PHASE1","PHASE2","This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.",[110,111],"Idiopathic Parkinson´s Disease","Parkinson's Disease",[26],"2026-01-22",{"date":115,"type":116},"2026-01-23","ACTUAL",{"date":118,"type":116},"2025-07-17",{"date":120,"type":103},"2031-06",{"name":5,"class":6},3]